85 Percent of CyberKnife® Sites Within Europe Performing Prostate Stereotactic Body Radiation Therapy (SBRT)

SUNNYVALE, Calif., May 11, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 85 percent of European CyberKnife® centers are performing prostate SBRT to treat localized prostate cancer. There is an increasing trend towards treating prostate cancer patients with a hypofractionated regimen.

"More than 25 percent of our CyberKnife patients are being treated for prostate cancer with further growth anticipated," said Dr David Feltl, Head of the Oncology department, Ostrava University Hospital, Ostrava, Czech Republic.

At the Annual Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO) in London, UK this growth was supported by strong clinical evidence presented at a symposium focused on prostate cancer co-chaired by Prof. Eric Lartigau, Centre Oscar Lambret, Lille, France, and Prof. Volker Budach, M.D., Ph.D., Charite – Universitatsmedizin Berlin, Germany.

"Offering CyberKnife non-invasive treatments to our patients provides excellent 5-year tumor control and very low level of toxicity as recently published in Radiation Oncology 2011," said Prof. Eric Lartigau.

"There is a strong academic interest to further drive prospective randomized clinical evidence for prostate SBRT with the CyberKnife System leading the clinical trend," said Prof. Volker Budach.

"The long term efficacy and toxicity outcomes of single and multi-center studies are supported by many key publications and presentations on CyberKnife prostate SBRT. Supported by an increasing foundation of solid clinical evidence we have seen a 20 percent increase in worldwide prostate cancer treatment as compared to a similar period last year," said Omar Dawood, vice president, Medical Affairs, Accuray Incorporated.

source: PR Newswire